| Literature DB >> 27602219 |
Dong Tian1, Hongying Wen1, Yu Zhou1, Maoyong Fu1.
Abstract
The present retrospective study was designed to review the clinicopathological features and outcome of surgical treatment of pulmonary chondroma, and to accumulate data for the clinical diagnosis and therapy. The clinicopathological data from 29 patients, aged between 38- and 78-years-old, with pulmonary chondroma who underwent surgical operation between July 2003 and June 2015 were reviewed. Of these patients, 18 exhibited no clinical symptoms, 7 were characterized by coughing, hemoptysis, shortness of breath and other symptoms and only 3 patients exhibited chest pain as the predominant symptom. The average size of the neoplasms was 3.6 cm. All patients were pathologically diagnosed. Operative time was 126±22 min, the mean intraoperative blood loss was 82±23 ml and the drainage duration was 3.1±1.8 days. A total of 6 postoperative complications were noted. The patients were followed-up for 2-135 months. A total of 23 patients were alive without recurrence, 4 patients succumbed to mortality, 2 patients were lost at follow-up. Pulmonary chondroma is a rare benign tumor of the lung. The clinical symptoms were concealed and often misdiagnosed as a tuberculosis tumor, hamartoma, peripheral lung cancer or a single metastatic tumor. Complete resection was the best treatment providing patients with a good prognosis. After definite diagnosis, it is necessary to exclude Carney's triad.Entities:
Keywords: clinicopathological features; pulmonary chondroma; surgical treatment
Year: 2016 PMID: 27602219 PMCID: PMC4998203 DOI: 10.3892/mco.2016.945
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450
Clinical data.
| Patient no. | Age (years) | Gender | Size (cm) | Operative time (min) | Blood loss (ml) | Drainage (days) | Follow-up | Position | Preoperative diagnosis |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 51 | M | 2.3 | 64 | 45 | 3 | Alive without recurrence | Right lower lobe | Hamartoma |
| 2 | 43 | F | 4.6 | 78 | 30 | 4 | Alive without recurrence | Right lower lobe | Benign nodules |
| 3 | 38 | M | 5.2 | 155 | 10 | 2 | Succumbed to non-neoplastic diseases | Right upper lobe | Hamartoma |
| 4 | 62 | M | 1.4 | 92 | 100 | 2 | Alive without recurrence | Right middle lobe | Benign nodules |
| 5 | 53 | M | 1 | 146 | 60 | 3 | Alive without recurrence | Right lower lobe | Hamartoma |
| 6 | 68 | F | 3.9 | 104 | 5 | 3 | Alive without recurrence | Left lower lobe | Hamartoma |
| 7 | 56 | F | 4.4 | 132 | 50 | 3 | Alive without recurrence | Right upper lobe | Benign nodules |
| 8 | 57 | F | 2.3 | 141 | 120 | 2 | Succumbed to non-neoplastic diseases | Right lower lobe | Hamartoma |
| 9 | 72 | F | 6.8 | 137 | 80 | 2 | Alive without recurrence | Left upper lobe | Benign nodules |
| 10 | 52 | M | 4.1 | 48 | 30 | 2 | Alive without recurrence | Right lower lobe | Hamartoma |
| 11 | 47 | F | 2.6 | 164 | 90 | 4 | Lost | Right lower lobe | Malignant tumor |
| 12 | 78 | M | 6.9 | 143 | 180 | 3 | Alive without recurrence | Left upper lobe | Benign nodules |
| 13 | 64 | M | 1.8 | 156 | 40 | 4 | Alive without recurrence | Left upper lobe | Benign nodules |
| 14 | 73 | F | 3 | 123 | 30 | 2 | Lost | Right middle lobe | Hamartoma |
| 15 | 66 | M | 2.5 | 157 | 75 | 5 | Alive without recurrence | Left lower lobe | Benign nodules |
| 16 | 69 | F | 5 | 129 | 350 | 2 | Alive without recurrence | Right lower lobe | Benign nodules |
| 17 | 64 | M | 8.5 | 92 | 40 | 3 | Succumbed to non-neoplastic diseases | Right middle lobe | Benign nodules |
| 18 | 57 | F | 3.8 | 201 | 60 | 2 | Alive without recurrence | Left upper lobe | Benign nodules |
| 19 | 52 | F | 3.2 | 107 | 80 | 8 | Alive without recurrence | Left lower lobe | Hamartoma |
| 20 | 55 | M | 1.9 | 215 | 240 | 3 | Alive without recurrence | Right lower lobe | Hamartoma |
| 21 | 58 | M | 1.8 | 104 | 30 | 4 | Alive without recurrence | Left upper lobe | Malignant tumor |
| 22 | 46 | F | 3.7 | 106 | 50 | 3 | Succumbed to non-neoplastic diseases | Left upper lobe | Hamartoma |
| 23 | 70 | F | 2.2 | 192 | 40 | 3 | Alive without recurrence | Left lower lobe | Benign nodules |
| 24 | 51 | M | 3.2 | 104 | 45 | 3 | Alive without recurrence | Left upper lobe | Benign nodules |
| 25 | 48 | M | 1.2 | 174 | 100 | 2 | Alive without recurrence | Left upper lobe | Hamartoma |
| 26 | 59 | F | 7.4 | 117 | 80 | 5 | Alive without recurrence | Right lower lobe | Hamartoma |
| 27 | 54 | M | 2.3 | 94 | 100 | 3 | Alive without recurrence | Left upper lobe | Benign nodules |
| 28 | 43 | M | 4.2 | 89 | 160 | 2 | Alive without recurrence | Left upper lobe | Benign nodules |
| 29 | 47 | M | 3.2 | 90 | 55 | 3 | Alive without recurrence | Left upper lobe | Hamartoma |
M, male; F, female.
Figure 1.Contrast-enhanced computed tomography revealed a large inhomogeneous density mass with varying degrees of calcification.
Figure 2.Images of the resected mass. (A) Patients with pulmonary chondroma underwent lobectomy intraoperatively. (B) The mass was pale and translucent, hard, and lobulated on the lateral section.
Figure 3.Hematoxylin and eosin staining of tumor cells. The tumor was revealed to be formed by differentiation of mature cartilage tissue wrapped around by cartilage matrix (magnification, ×200).